Nipun Davar

Transcept Pharmaceuticals, Inc. researches and develops biopharmaceutical products. The firm's products are used for pain, side effects of chemotherapy treatments, sleeplessness, and migraine headaches. Its drug delivery technology enhances absorption rates of active drug agents reduces absorption times. The company was founded in January, 2002 by Nikhilesh Singh and is headquartered in Pt. Richmond, CA.

Transcept Pharmaceuticals, Inc. researches and develops biopharmaceutical products. The firm's products are used for pain, side effects of chemotherapy treatments, sleeplessness, and migraine headaches. Its drug delivery technology enhances absorption rates of active drug agents reduces absorption times. The company was founded in January, 2002 by Nikhilesh Singh and is headquartered in Pt. Richmond, CA.

Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA

Transcept Pharmaceuticals, Inc. researches and develops biopharmaceutical products. The firm's products are used for pain, side effects of chemotherapy treatments, sleeplessness, and migraine headaches. Its drug delivery technology enhances absorption rates of active drug agents reduces absorption times. The company was founded in January, 2002 by Nikhilesh Singh and is headquartered in Pt. Richmond, CA.

Transcept Pharmaceuticals, Inc. researches and develops biopharmaceutical products. The firm's products are used for pain, side effects of chemotherapy treatments, sleeplessness, and migraine headaches. Its drug delivery technology enhances absorption rates of active drug agents reduces absorption times. The company was founded in January, 2002 by Nikhilesh Singh and is headquartered in Pt. Richmond, CA.

Transcept Pharmaceuticals, Inc. researches and develops biopharmaceutical products. The firm's products are used for pain, side effects of chemotherapy treatments, sleeplessness, and migraine headaches. Its drug delivery technology enhances absorption rates of active drug agents reduces absorption times. The company was founded in January, 2002 by Nikhilesh Singh and is headquartered in Pt. Richmond, CA.

Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA

Transcept Pharmaceuticals, Inc. researches and develops biopharmaceutical products. The firm's products are used for pain, side effects of chemotherapy treatments, sleeplessness, and migraine headaches. Its drug delivery technology enhances absorption rates of active drug agents reduces absorption times. The company was founded in January, 2002 by Nikhilesh Singh and is headquartered in Pt. Richmond, CA.

Transcept Pharmaceuticals, Inc. researches and develops biopharmaceutical products. The firm's products are used for pain, side effects of chemotherapy treatments, sleeplessness, and migraine headaches. Its drug delivery technology enhances absorption rates of active drug agents reduces absorption times. The company was founded in January, 2002 by Nikhilesh Singh and is headquartered in Pt. Richmond, CA.

Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA

Transcept Pharmaceuticals, Inc. researches and develops biopharmaceutical products. The firm's products are used for pain, side effects of chemotherapy treatments, sleeplessness, and migraine headaches. Its drug delivery technology enhances absorption rates of active drug agents reduces absorption times. The company was founded in January, 2002 by Nikhilesh Singh and is headquartered in Pt. Richmond, CA.

Transcept Pharmaceuticals, Inc. researches and develops biopharmaceutical products. The firm's products are used for pain, side effects of chemotherapy treatments, sleeplessness, and migraine headaches. Its drug delivery technology enhances absorption rates of active drug agents reduces absorption times. The company was founded in January, 2002 by Nikhilesh Singh and is headquartered in Pt. Richmond, CA.

Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA

Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA

Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA